{"nctId":"NCT01433107","briefTitle":"Efficacy and Safety of Terbinafine Film Forming Solution in Patients With Tinea Pedis","startDateStruct":{"date":"2011-08"},"conditions":["Tinea Pedis"],"count":290,"armGroups":[{"label":"Terbinafine","type":"EXPERIMENTAL","interventionNames":["Drug: Terbinafine"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Terbinafine Placebo"]}],"interventions":[{"name":"Terbinafine","otherNames":[]},{"name":"Terbinafine Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients â‰¥18 years of age with interdigital tinea pedis infection, with clinical diagnosis meeting required baseline total sign \\& symptom score and positive microscopy\n\nExclusion Criteria:\n\n* Allergy to the allylamine class of antimycotics or excipients in the formulation.\n* Chronic, hyperkeratotic plantar (moccasin) tinea pedis\n* Other fungal disease or intertrigo\n* Other abnormal findings on the affected foot\n* Systemic antifungal or antimicrobial treatment within the last 3 months\n* Topical treatment for skin lesions on feet within the last 3 months\n* Diabetes mellitus and peripheral artery occlusive disease","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Effective Treatment Outcome (Direct Microscopy and Culture Negative and Total Signs and Symptom Score Less or Equal to 2)","description":"Each clinical sign or symptom will be assessed separately. The investigator will evaluate the severity of each sign or symptom over the entire target foot. Clinical signs and symptoms including desquamation (scaling), erythema, incrustation (crusting), pustules, vesiculation and pruritus will be evaluated by the investigator or designee and recorded at every visit using the following scale:\n\n0 = absent\n\n1. = mild\n2. = moderate\n3. = severe In order to calculate the total symptoms score the rating for all symptoms are added up.\n\nPossible range 0 to 18","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Clinical Signs and Symptoms (S/S) Scores","description":"Each clinical sign or symptom will be assessed separately. The investigator will evaluate the severity of each sign or symptom over the entire target foot. Clinical signs and symptoms including desquamation (scaling), erythema, incrustation (crusting), pustules, vesiculation and pruritus will be evaluated by the investigator or designee and recorded at every visit using the following scale:\n\n0 = absent\n\n1. = mild\n2. = moderate\n3. = severe In order to calculate the total symptom score, the scores for each individual symptom are added up.\n\nPossible range : 0 to 18","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":null},{"groupId":"OG001","value":"4.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Adverse Event","description":"Number of Subjects with adverse event","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":146},"commonTop":["General Disorders"]}}}